

FORM F

The Growth Enterprise Market (GEM) Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: 山東威高集團醫用高分子製品股份有限公司
(Shandong Weigao Group Medical Polymer Company Limited*)

Stock code (H Shares): 8199

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 29 December 2008.

A. General

Place of incorporation :	People's Republic of China
Date of Initial listing on the GEM:	27 February 2004
Name of Sponsor:	N/A
Names of Directors:	<u>Executive Directors:</u> Zhang Hua Wei (張華威) Miao Yan Guo (苗延國) Wang Yi (王毅) Wang Zhi Fan (王志范) Wu Chuan Ming (吳傳明) <u>Non-Executive Directors</u> Chen Xue Li (陳學利) Zhou Shu Hua (周淑華) Li Bing Yung (李炳容) Jean Luc Butel

Independent Non-executive Directors

Shi Huan (石暉)

Luan Jian Ping (樂建平)

Li Jia Miao (李家淼)

Lau Wai Kit (劉偉傑)

Name(s) of substantial shareholder(s) (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company :

威高集團有限公司(Weigao Holding Company Limited*)
532,438,919 Domestic Shares, 49.47% of total issued share capital

Medtronic Holding Switzerland G.m.b.H
80,721,081 Domestic Shares and 80,721,081 H Shares
15.00% of total issued share capital

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company :

N/A

Financial year end date :

December 31

Registered address :

312 Shichang Road
Weihai
Shandong
PRC

Head office and principal place of business :

312 Shichang Road
Weihai
Shandong
PRC

Web-site address (if applicable) :

www.weigaogroup.com

Share registrar and transfer office:

Tricor Standard Limited

Auditors:

Deloitte Touche Tohmatsu

B. Business activities

The Company is principally engaged in the research and development, production and sale of single-use medical devices. The Group has a wide range of products, which includes: i) consumables (infusion set, syringes, medical needle, blood bags, dental and anaesthetic consumables, blood sampling products, and other consumables); ii) orthopedic materials; iii) blood purification consumables; iv) medical and non-medical PVC granules; and v) stent.

C. Ordinary shares

Number of H Shares in issue:	428,121,081 H Shares
Par value of H shares in issue:	RMB0.10
Board lot size (in number of H Shares):	4,000
Name of other stock exchange(s) on which H shares are also listed :	N/A

D. Warrants

Stock code:	N/A
Board lot size:	N/A
Expiry date:	N/A
Exercise price :	N/A
Conversion ratio: (Not applicable if the warrant is denominated in dollar value of conversation right)	N/A
No of warrant outstanding:	N/A
No. of shares falling to be issued upon the exercise of outstanding warrants:	N/A

E. Other securities

N/A

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

** For identification purposes only*

Signed by:

Zhang Hua Wei (張華威)

Chen Xue Li (陳學利)

Wu Chuan Ming (吳傳明)

Wang Yi (王毅)

Wang Zhi Fan (王志范)

Miao Yan Guo (苗延國)

Zhou Shu Hua (周淑華)

Li Bing Yung (李炳容)

Jean Luc Butel

Shi Huan (石暉)

Luan Jian Ping (樂建平)

Li Jia Miao (李家淼)

Lau Wai Kit (劉偉傑)